GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Primary Purpose
Obesity
Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
GLP-1 analogue - semaglutide
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- BMI ranging from 30-49.9 kg/m2
- No significant medical problems, including diabetes
- No history of HgbA1c <6.5%
- English speaking and able to read English and complete study evaluations
- Able to provide informed written and verbal consent
Exclusion Criteria:
- Any significant current medical conditions, including neurological, renal, thyroid, cardiovascular, liver, endocrine or immune conditions, including diagnosis of T2DM or T1DM by American Diabetes Association (ADA) criteria
- Meet current or past DSM-IVR criteria for alcohol dependence or any substance use disorders, including nicotine, or psychiatric disorders, including eating disorders, or use of any psychiatric medications, including anxiolytics, antidepressants, naltrexone or antabuse, anti-smoking medications
- Current active participation in a weight loss program or weight loss of >10% of total body weight during the prior 6 months
- Taking any other anti-obesity medication
- History of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who are pregnant or lactating, or peri/postmenopausal
Sites / Locations
- The Yale Stress Center: Yale UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
GLP-1a
Placebo
Arm Description
GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks
Placebo pen administered weekly over 12 weeks
Outcomes
Primary Outcome Measures
Change in Craving
Craving will be measured using a validated questionnaire called Food Craving Scale (FCS). FCS is an 28-item questionnaire that measures how often participates experienced a craving for a food type. Participants can respond to each item from "never" to "always/ almost every". HIgher scores indicate greater craving.
Change in Hunger
Hunger will be measured in a Visual Analog Scale (VAS) range from 0 to 9. Higher VAS indicates greater hunger.
Change in Food Intake
Food intake will be measured in KCalories during a validated observed laboratory task
Secondary Outcome Measures
Change in weight
Weight in kilograms will be assessed using a bioimpedance scale
Change in food intake - real-life
Food intake will be measured in Kcalories using 3-day 24hr recall (ASA24)
Change in stress
Stress, measured as total score on the 14-item Perceived Stress Scale, with higher scores indicating greater subjective stress.
Full Information
NCT ID
NCT04779697
First Posted
February 10, 2021
Last Updated
December 14, 2022
Sponsor
Yale University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT04779697
Brief Title
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Official Title
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2021 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
5. Study Description
Brief Summary
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Detailed Description
A randomized, double-blind, placebo-controlled 12-week study with GLP-1 analogue (semaglutide) in men and women with obesity (BMI 30-49.9 kg/m2) in a validated laboratory model to identifying processes underlying greater food craving, intake and weight change, in order to test mechanisms by which a GLP-1 analogues may exerts significant weight effects in obesity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
96 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
GLP-1a
Arm Type
Experimental
Arm Description
GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo pen administered weekly over 12 weeks
Intervention Type
Drug
Intervention Name(s)
GLP-1 analogue - semaglutide
Other Intervention Name(s)
Semaglutide
Intervention Description
GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo - administered once weekly for a total of 12 weeks
Primary Outcome Measure Information:
Title
Change in Craving
Description
Craving will be measured using a validated questionnaire called Food Craving Scale (FCS). FCS is an 28-item questionnaire that measures how often participates experienced a craving for a food type. Participants can respond to each item from "never" to "always/ almost every". HIgher scores indicate greater craving.
Time Frame
week 0 and week 12
Title
Change in Hunger
Description
Hunger will be measured in a Visual Analog Scale (VAS) range from 0 to 9. Higher VAS indicates greater hunger.
Time Frame
week 0 and week 12
Title
Change in Food Intake
Description
Food intake will be measured in KCalories during a validated observed laboratory task
Time Frame
week 0 and week 12
Secondary Outcome Measure Information:
Title
Change in weight
Description
Weight in kilograms will be assessed using a bioimpedance scale
Time Frame
weekly for 12 weeks
Title
Change in food intake - real-life
Description
Food intake will be measured in Kcalories using 3-day 24hr recall (ASA24)
Time Frame
week 0, 4, 8, 12
Title
Change in stress
Description
Stress, measured as total score on the 14-item Perceived Stress Scale, with higher scores indicating greater subjective stress.
Time Frame
week 0, 4, 8, 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
BMI ranging from 30-49.9 kg/m2
No significant medical problems, including diabetes
No history of HgbA1c <6.5%
English speaking and able to read English and complete study evaluations
Able to provide informed written and verbal consent
Exclusion Criteria:
Any significant current medical conditions, including neurological, renal, thyroid, cardiovascular, liver, endocrine or immune conditions, including diagnosis of T2DM or T1DM by American Diabetes Association (ADA) criteria
Meet current or past DSM-IVR criteria for alcohol dependence or any substance use disorders, including nicotine, or psychiatric disorders, including eating disorders, or use of any psychiatric medications, including anxiolytics, antidepressants, naltrexone or antabuse, anti-smoking medications
Current active participation in a weight loss program or weight loss of >10% of total body weight during the prior 6 months
Taking any other anti-obesity medication
History of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who are pregnant or lactating, or peri/postmenopausal
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ania Jastreboff, MD, PhD
Phone
(203) 737-5015
Email
ania.jastreboff@yale.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Rajita Sinha, PhD
Phone
(203) 737-1272
Email
rajita.sinha@yale.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ania Jastreboff, MD, PhD
Organizational Affiliation
Internal Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology);
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rajita Sinha, PhD
Organizational Affiliation
Psychiatry; Director Yale Stress Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Yale Stress Center: Yale University
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Seungju Hwang, BS
Phone
203-737-4011
Email
seungju.hwang@yale.edu
First Name & Middle Initial & Last Name & Degree
Ania Jastreboff, MD, PHD
Email
ania.jastreboff@yale.edu
First Name & Middle Initial & Last Name & Degree
Ania Jastreboff, MD, PhD
12. IPD Sharing Statement
Learn more about this trial
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
We'll reach out to this number within 24 hrs